Johns Hopkins Finds Weeks 10-14 Cone Shift Builds Sharp Vision With Vitamin A and Thyroid Hormones
Updated
Updated · ScienceDaily · Jul 9
Johns Hopkins Finds Weeks 10-14 Cone Shift Builds Sharp Vision With Vitamin A and Thyroid Hormones
1 articles · Updated · ScienceDaily · Jul 9
Summary
Blue cone cells in the fetal retina do not migrate away from the center as long thought; Johns Hopkins researchers found they convert into red and green cones between weeks 10 and 14.
Lab-grown retinal organoids showed a two-step process: retinoic acid—a vitamin A-derived molecule—falls first, limiting new blue cones, then thyroid hormones push remaining blue cones to change identity.
The finding overturns a roughly 30-year model for how the foveola forms, the tiny retinal center responsible for about half of human visual perception and the sharpest vision.
PNAS published the study, which researchers say could improve retinal organoids and eventually support cell-replacement therapies for macular degeneration, glaucoma and other vision-loss diseases.
How soon could this lab discovery for sharp vision actually lead to a cure for macular degeneration patients?
A decades-old theory on vision was just overturned. What other fundamental medical 'facts' might be completely wrong?
If eye cells can transform their identity, could we reprogram other cells in the body to fight disease?
New Study Overturns 30-Year Theory: How Cone Conversion in the Fetal Foveola Enables High-Acuity Vision
Overview
A groundbreaking 2026 study from Johns Hopkins University has transformed our understanding of how sharp vision develops before birth. Previously, experts believed that the foveola—the retina’s center for high-acuity vision—formed through the migration of blue cone photoreceptors. The new research overturned this 30-year-old theory, revealing instead that a precise process of cell conversion happens directly within the foveola. This discovery highlights how specialized cone cells, essential for color and daytime vision, are carefully orchestrated during fetal development, offering new hope for treating vision disorders and advancing future therapies.